Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases: Rationale, Aims, and Design of a Nationwide Prospective Registry—The EXCITING-ILD Registry

Despite a number of prospective registries conducted in past years, the current epidemiology of interstitial lung diseases (ILD) is still not well defined, particularly regarding the prevalence and incidence, their management, healthcare utilisation needs, and healthcare-associated costs. To address these issues in Germany, a new prospective ILD registry, “Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases” (EXCITING-ILD), is being conducted by the German Centre for Lung Research in association with ambulatory, inpatient, scientific pulmonology organisations and patient support groups. This multicentre, noninterventional, prospective, and observational ILD registry aims to collect comprehensive and validated data from all healthcare institutions on the incidence, prevalence, characteristics, management, and outcomes regarding all ILD presentations in the real-world setting. Specifically, this registry will collect demographic data, disease-related data such as ILD subtype, treatments, diagnostic procedures (e.g., HRCT, surgical lung biopsy), risk factors (e.g., familial ILD), significant comorbidities, ILD managements, and disease outcomes as well as healthcare resource consumption. The EXCITING-ILD registry will include in-patient and out-patient ILD healthcare facilities in more than 100 sites. In summary, this registry will document comprehensive and current epidemiological data as well as important health economic data for ILDs in Germany.

[1]  H. Sørensen,et al.  The incidence of interstitial lung disease 1995–2005: a Danish nationwide population-based study , 2008, BMC pulmonary medicine.

[2]  Shandra L. Protzko,et al.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. , 2013, American journal of respiratory and critical care medicine.

[3]  Paul J. Friedman,et al.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors , 2002, American journal of respiratory and critical care medicine.

[4]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[5]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[6]  A. Azuma,et al.  A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis , 2015 .

[7]  O. Turan,et al.  Epidemiology and distribution of interstitial lung diseases in Turkey , 2014, The clinical respiratory journal.

[8]  R. Balbontín,et al.  [Interstitial lung diseases]. , 1985, Revista medica de Chile.

[9]  K. Brown,et al.  Sarcoidosis-related mortality in the United States from 1988 to 2007. , 2011, American journal of respiratory and critical care medicine.

[10]  M. Demedts,et al.  REGISTRATION OF INTERSTITIAL LUNG DISEASES BY 20 CENTRES OF RESPIRATORY MEDICINE IN FLANDERS , 2001, Acta clinica Belgica.

[11]  C. Burger Efficacy and safety of sirolimus in lymphangioleiomyomatosis. , 2011, The New England journal of medicine.

[12]  J. Ancochea,et al.  Report on the incidence of interstitial lung diseases in Spain. , 2004, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[13]  J. López-Campos,et al.  Incidence of interstitial lung diseases in the south of Spain 1998–2000: The RENIA study , 2003, European Journal of Epidemiology.

[14]  A. Wells,et al.  The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation. , 2015, Health technology assessment.

[15]  Workman Ta,et al.  Engaging Patients in Information Sharing and Data Collection: The Role of Patient-Powered Registries and Research Networks , 2013 .

[16]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.

[17]  R. Hubbard,et al.  Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK , 2006, Thorax.

[18]  U. Costabel,et al.  Wie werden interstitielle Lungenerkrankungen in Deutschland diagnostiziert , 2003 .

[19]  C. Reinero,et al.  Interstitial lung diseases. , 2007, The Veterinary clinics of North America. Small animal practice.

[20]  D. Bouros,et al.  Epidemiology of interstitial lung diseases in Greece. , 2009, Respiratory medicine.

[21]  R. Hubbard,et al.  Interstitial lung diseases: an epidemiological overview. , 2001, The European respiratory journal. Supplement.

[22]  W. Black,et al.  The epidemiology of interstitial lung diseases. , 1994, American journal of respiratory and critical care medicine.

[23]  H. Schweisfurth [Report by the Scientific Working Group for Therapy of Lung Diseases: German Fibrosis Register with initial results]. , 1996, Pneumologie.

[24]  Tutut Herawan,et al.  Computational and mathematical methods in medicine. , 2006, Computational and mathematical methods in medicine.

[25]  T. Welte,et al.  Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry , 2015, European Respiratory Journal.

[26]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[27]  R. Sussman,et al.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[28]  M. Demedts,et al.  Epidemiology of interstitial lung-disease (ild) in flanders - registration by pneumologists in 1992-1994 , 2016 .